Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label, Phase III Study.
Hermine I BrunnerCésar Pacheco-TenaIngrid LouwGabriel Vega-CornejoEkaterina AlexeevaSimone AppenzellerVyacheslav ChasnykThomas GriffinCarmen Navarrete SuarezSheila Knupp-OliveiraAndrew ZeftYonatan Butbul AvielDeirdre De RanieriBeth S GottliebDeborah M LevyC Egla RabinovichClóvis Artur SilvaYury SpivakovskyYosef UzielSarah RingoldXie L XuJocelyn H LeuEdwin LamYuhua WangDaniel J LovellAlberto MartiniNicolino Rupertonull nullPublished in: The Journal of rheumatology (2024)
GO-VIVA LTE participants experienced adequate PK exposure and stable safety and immunogenicity. The majority of participants experienced no more than minimal residual disease activity. Data suggest IV golimumab treatment provided durable clinical response through week 116, with an acceptable risk-benefit profile.
Keyphrases
- juvenile idiopathic arthritis
- disease activity
- ankylosing spondylitis
- phase iii
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- open label
- clinical trial
- placebo controlled
- young adults
- double blind
- electronic health record
- big data
- ulcerative colitis
- randomized controlled trial
- machine learning
- combination therapy
- low dose
- deep learning